Sanofiís Colorectal Cancer Drug Receives FDA Approval

by Kathy Jones on  August 4, 2012 at 7:42 PM Drug News
RSS Email Print This Page Comment bookmark
Font : A-A+

Sanofi revealed that the US Food and Drug Administration has approved its metastatic colorectal cancer drug Zaltrap which has been developed in collaboration with Regeneron Pharmaceuticals.
 Sanofiís Colorectal Cancer Drug Receives FDA Approval
Sanofiís Colorectal Cancer Drug Receives FDA Approval

The company said that Zaltrap could be effective in colorectal cancer patients who have not responded to chemotherapy treatment. Large scale clinical trials showed that people taking Zaltrap along with FOLFIRI chemotherapy combination regimen lived for 13.5 months compared to 12 months for those who received only FOLFIRI.

Zaltrap is expected to compete against Roche's Avastin and Bristol-Myers Squibb's Erbitux with analysts predicting that it could have peak annual sales of $300 million to $400 million. "While near-term we expect (Regeneron's) stock will continue to trade primarily on the Eylea launch which remains impressive, we view Zaltrap's approval as a nice complement to what is rapidly becoming one of biotech's best commercial stories", RW Baird analyst Christopher Raymond said.

Source: Medindia

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions

More News on:

Drug Toxicity Cancer and Homeopathy Colo-rectal cancer - Management Colorectal Cancer Signature Drug Toxicity Cancer Facts Cancer Tattoos A Body Art Colon Polyps Colorectal Cancer Screening 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Stay Connected

  • Available on the Android Market
  • Available on the App Store

News Category

News Archive

Loading...